New video from cvsi and driftless farms.

USDA guidance requirements for hemp farming are due any day. Anyone else
think that CV Sciences has been waiting for these guidelines to maybe buying their own farm? I see Driftless Extracts LLc in February submitted to the SEC a form D to raise 5 million. February was also the submission date for New Harvest.
I can visualize a certified organic hemp farm providing cbd for New Harvest
and fiber to Patagonia.

We have a new advisory board member.
Christopher Mohr, PhD RD is a nutrition spokesperson and consultant to a number of media outlets and corporations. He is the co owner of the Well Being Consulting Company, Mohr Results, Inc, which is offered the opportunity to speak and teach to groups around the world. Current and past clients include Under Armour, Johnson and Johnson, the Johnson and Johnson Human Performance Institute, Deloitte, General Mills Bell Institute of Health, Clif Bar, Barilla, Gatorade, Nestle and Nordic Naturals, among others.

Dr. Mohr was the consulting Sports Nutritionist for the Cincinnati Bengals, works with select WWE Athletes and his expertise has offered him the opportunity to speak at the White House, the CIA and to audiences in over 10 countries and almost all 50 states.

He often appears on TV as a nutritional guest expert, including an appearance with Chef Emeril Lagasse, CBS’s ‘The Talk’ and another on the Montel Williams Show. He was the nutrition consultant and expert for the NY Times Bestseller, “LL Cool J’s Platinum Workout” and worked closely with Fitness Celebrity Denise Austin & Mario Lopez, to write the nutrition sections for their books.

Dr. Mohr has Bachelor and Master of Science degrees in Nutrition from The Pennsylvania State University and University of Massachusetts, respectively. He earned his PhD in exercise physiology from the University of Pittsburgh and is a Registered Dietitian.
https://pluscbdoil.com/advisory-board/

Looks like they are beginning to package new line of items in boxes.
Attractive packaging.Should be a great revenue generator, Nice find

This Wisconsin farming company is hopeing for a multi million dollar contract with cv sciences to grow hemp the "european model" way. Begin listening at 45:30

It looks like Patagonia is buying the bottom 2/3 of the plant
and cv sciences the tops from Butler farms.
https://www.kentucky.com/news/business/article231684938.html

New video shows how farmers benefit with two checks. One from cvsi for flowers and another check from other companies for the fiber

Employee count is up to 120 a 50% increase from Jan.1.
Moving into a new facility that will allow growth upwards of 400%.
What we're seeing now in share price is pure and simple market psychology
not fundamentals. Buying

Excellent letter from congress to FDA telling them they already have the authority for lower doses of cbd fpr supplements and higher doses for medicine. In line with what cvsi has been saying. Beginning to bottom feed.

https://www.marijuanamoment.net/bipartisan-lawmakers-call-on-fda-to-clear-a-path-for-cbd-companies/

If you check the patent website you'll see the decision was made
Friday but the reasons for the decision was just published late Tuesday.
The reasons were 17 pages just emailed late to the lawyers on the 17th.
Give them a day to confer and decide what to do based on reasons for decision. Looks like they handled this appropriately

You said:
"People just can't comprehend what kind of precedent the FDA would set by allowing classified drug ingredients to be in the food supply."

The precedent has already been set and this is why cvsi has been telling
the FDA no new standards need to be set.

Lovaza(a drug) (omega-3-acid ethyl esters) is generally considered to be more concentrated than OTC fish oil supplements. It is available in 1-gram capsules that contain approximately 375 mg DHA and 465 mg EPA (total of 840 mg omega-3). In contrast, OTC fish oil supplements contain varying amounts of EPA and DHA

Encouraging that the heavyweights Tilray and Canopy both had 52 week lows
on August 30th. They then proceeded to gain as much as 30% before settling
down to 20% today. This tells me big money may believe the sector has bottomed. Some of you are taking this too cvsi personally.

Looking into the correlation that both cvsi and cw have partnered
with the Rodale Institute in regards to hemp regenerative agriculture.
CVSI about a year ago and CW just in July( eight months later) proclaiming they were
pioneering hemp regenerative agriculture with Rondale.
I see Rondale will be offering two different"seal of approval" for products
that meet their standards.One seems much more difficult to attain then the other but either one would be beneficial to have on your labeling

Just to keep it real,IMHO there is no Japanese patent.
The source of the rumor mistakenly identified the publishing of the
application by the Japanese Patent Office in June as a actual granting
of the patent. Publishing the application is just a step in the process.
In all countries applied "Legal status Pending"

https://patents.google.com/patent/JP2019514990A/en

I also believe there is so much potential here without the patents.
To quote my favorite author Alfred E. Neuman, "what me worry"

You have to go to the patent website and search for it.
https://portal.uspto.gov/pair/PublicPair.

looks like a decision has been rendered. Examiner affirmed. Which i believe means no patent for 007 unless they take it to court of appeals.

The patent oral transcripts are posted for those who have access.
After reading the 12 pages its still hard to ascertain the way the three
judges are leaning. CVSI council seems to make the point the examiner uses
hindsight which is inadmissible in his denial of some of the claims.

I believe Spacelady knows how to post transcripts here.

In case you missed the CV Sciences's Josh Hendrix earlier you can watch here on youtube. Talking about NDI's and GRAS and FDA
Begins about -47 minutes. Earlier sessions were also very informative.

Live cam from Expo East the hemp and cbd expo. Josh Hendrix beginning
9:50 eastern.
https://www.newhope.com/ingredients/livestream-expo-east-2019-natural-products-hemp-and-cbd-summit?utm_rid=CNHNM000004301290&utm_campaign=NHN_EE19_Livestream_Wednesday_EB_091119&utm_medium=email&utm_source=Eloqua

Yesterday FDA revamped the NDI submission process which will
cover the trade secrets and confidential information companies
were concerned about.
This may be a indication of the guidance the FDA will be presenting
concerning requirements for cbd soon.
https://www.fda.gov/media/130380/download

I used the code TUCK and received 20% off last week. It seems to still apply.
https://www.tuck.com/pluscbd-cbd-review/

Statement from Aguiar on CA AB 228.

"I am confident that we will have a bill ready for the Governor to sign at the beginning of next year"

https://www.davisvanguard.org/2019/09/assemblymember-cecilia-aguiar-curry-responds-to-the-senate-appropriations-committee-holding-ab-228-on-suspense/

Okay I see it listed for both the assembly and senate appropriations
meeting beginning 10:30. Thanks Dean

I see its on but AB228 is not listed on the agenda of the link you provided.
I see in the status that there is a committee session scheduled for
AB228 but that may be a different room?

Reading again the Nasdaq requirements for the Audit committee it would seem the new director would also need to be added to that committee to fulfill the three "independent" rule. You'll recall Sligar, who was on the audit committee resigned in June. We may have a additional new BOD soon?

Nasdaq: I hereby certify that the Company has, and will continue to have, an Audit Committee of at least three members, comprised solely
of directors each of whom: (1) meets Nasdaq's definition of independence contained in Rule 5605(a)(2)

Nasdaq new listing requirements effective August 2019.
Possible tie-in to new director? https://listingcenter.nasdaq.com/assets/initialguide.pdf

She fulfills the Nasdaq as a "independance"

From CV Sciences Charter:
"The Committee shall be comprised of at least two directors. All members of the
Committee shall meet the “independence” and other applicable requirements of the NASDAQ
Stock Market. The Company’s Board shall appoint, and may replace, members of the
Committee and the Committee’s chairperson (the “Chairman”)."

https://d1io3yog0oux5.cloudfront.net/_0de36147e8a5c3f4f732dee994125030/cvsciences/db/371/2685/file/Nominating+%26+Gov+Committee+Charter.pdf

Pretty sure it wasn't your intention but your link actually shows a decrease of over 5 million (dilutive)shares the last six months
Dec. 18. 2018 shows 126.08 (dilutive)
June 19, 2019 shows 120.93 (dilutive)
Thank you

No company is better positioned for any regulations that the FDA may require.
Listen and listen again to what Duffy Mackay anticipates will be the FDA
pathway. Begin Minute 11 https://ir.cvsciences.com/presentations/detail/2697/video-cv-sciences-inc-2019-shareholders-meeting---june

Structure/function claim for lowering cholesterol
or changing hemoglobin A1C in CV Sciences future?

During the May 16 Public Meeting to Discuss Responsible Innovation in Dietary Supplements(375 pages of transcripts) after two officials from Health Canada presented.

"So this is Doug MacKay from CV Sciences. I’m just curious from both your
perspectives. The arbitrary line that we have here in
the United States that products can only support
normal health, and then you guys were able to venture
into this area with natural products can actually have
a therapeutic benefit. That seems to translate a lot
of the issues that we talk about, even getting the
right kind of evidence to make a claim becomes
difficult if we can’t talk about lowering cholesterol
or changing hemoglobin A1C.
So just philosophically, how much does
that shape the regulatory paradigm and what advice
would you give to the United States on that topic?"

Here's one for Jefra.
https://finance.yahoo.com/news/better-cbd-stock-charlotte-apos-124600976.html

After a flurry of activity in July the trademark Canteen will be published
09/17/2019. For those of you who have reservations about their pharmaceutical
business side one should take notice of how epidiolex sold 60m instead of
the forcasted 20m for the quarter.

Must read or listen.Great insights to behind the scenes. Hang on people
This industry is just about to kick in.
https://www.canneconomy.com/podcasts/ep-458-josh-hendrix-us-hemp-roundtable/

Josh Hendrix: The folks that we're working with this year as far as CV Science is going, they're going to get two checks. One from whoever they sell the straw too, and one from us for the floral material. If the government was going to offer them a third check to keep them doing it once we figure to the numbers and where that all lines out, that would obviously be a huge benefit to the industry. Will it be necessary? I don't know. But right now, the farmers I've talked to, they'll take every dollar they can get. So we give them two checks, they're ecstatic. They found out the that the European farmers get a third, they're going, "Oh, man. Let's hope that comes down the pipeline one day."

This patent discussion could be a moot point. Cv sciences has always referred to their process as proprietary. I'm not convinced they are even following their patent process.
"Through a proprietary chemical-free process, we convert our raw CO2-extracted oil into varying concentrations of our hemp-derived CBD oil."

He's being extra cautious with this sector in light that it was
just six months ago that he raised his stock price target
for Canopy from $40 to $60.

Directed to me?
"You thought this earnings report was bad?"
No, i thought it was good.
"Can anybody read what it says on that wall?"
I read 150% year over year EPS (2019-2020)

It may be good that JP.issued guidance that on the surface looks easy to beat and allow him to raise price targets.

"Equities researchers at Piper Jaffray Companies issued their Q3 2019 earnings estimates for CV Sciences in a note issued to investors on Monday, August 12th. Piper Jaffray Companies analyst M. Lavery anticipates that the company will post earnings per share of $0.01 for the quarter. Piper Jaffray Companies has a “Overweight” rating and a $5.00 price objective on the stock. Piper Jaffray Companies also issued estimates for CV Sciences’ Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.04) EPS, Q1 2020 earnings at $0.01 EPS, Q2 2020 earnings at $0.02 EPS, Q3 2020 earnings at $0.03 EPS, Q4 2020 earnings at $0.04 EPS and FY2020 earnings at $0.10 EPS".

Full text of speech August 13.

"And if we conclude that we need additional authorities or resources, we’ll need to think about going back to Congress."

https://www.fda.gov/news-events/speeches-fda-officials/remarks-national-industrial-hemp-council-2019-hemp-business-summit-08132019

New FDA guidance?
"According to the Principal Associate Commissioner for Policy of the FDA, Lowell Schiller, who spoke in front of the National Industrial Hemp Council, CBD will be treated the same way any other new ingredient would be initially introduced, hence the reason for requesting research-backed findings. The latter must show evidence of “dosing and drug interactions,” before it can be considered for over-the-counter services."

https://hempindustrydaily.com/fda-unlikely-to-grant-cbd-exception/

Mitch just today penned a story citing a global company interested in Kentucky industrial hemp. Interested in fiber not cbd.
http://kentuckytoday.com/stories/kentucky-in-lead-with-industrial-hemp,2101

I agree in principle with what you are saying but believe its still a matter of knowing who you're dealing with (FDA and Pharmaceuticals)
They can severely hinder the industry but seem to be flexible in allowing
a minimal entry point.

“We think that the USDA and FDA (U.S. Food and Drug Administration) will eventually (recommend food and fiber hemp varieties) primarily because there is precedent elsewhere in the world and we don’t have to reinvent the wheel,” Tomc said.